



The Digital Examiner

www.prostaid.org

275 September 2022

“I could walk a mile in your shoes, but I already know they’re just as uncomfortable as mine. Let’s walk next to each other instead.

Lynda Meyers

Connect with us:

Information

Phone: 403-455-1916

info@prostaid.org

Brad Sterling

President

president@prostaid.org

Support Groups

Frank Altin Warriors

faltin@telusplanet.net

Wives, Partners & Caregivers

info@prostaid.org

Newly Diagnosed

info@prostaid.org

Mailing Address

PROSTAID Calgary Society

PO Box 72126

RPO Glenmore Landing

Calgary, Alberta

T2V 5H9

Phone: 403-455-1916

To subscribe to The Digital Examiner

info@prostaid.org

PROSTAID Calgary
is self-funded.

[Click here to help us
to continue our
good work by
donating on-line](#)

Next Meeting :

**Tuesday, September 13th,
2022**

7 pm—9 pm

Grey Eagle Hotel

****Please note this is an IN-PERSON
meeting and will NOT be available on
Zoom.**

Side Bar:

**Welcome back! Hoping to
see all of you face-to-face
at the General Meeting.**

Our ongoing fundraising, the Pro-
gressive 50/50 goes until Septem-
ber 30. Please help us get that
amount up to the maximum. Link
is on the website:

www.prostaid.org



Stay healthy,
Dorothy

Dorothy Rodehutsors
Program Director



**PLEASE JOIN US ON
September 13th, 7 pm
In recognition of
PROSTATE Cancer
Awareness Month**

- ◇ Refreshments provided
- ◇ Engaging discussion
- ◇ Supportive sharing

**RSVP by email, phone, or
on website**

What's new in RESEARCH:

What's new generally:

[Entering A New Era of Robotic Surgery: Robot-Assisted Radical Prostatectomy with the Novel "HUGO" Robotic System](#)

- ◇ The last two decades have witnessed a significant evolution and a huge widespread of robotic-assisted surgical systems. On the other hand, access to robotic surgery has been limited by platforms availability and by concerns regarding cost-effectiveness.
- ◇ July 2022

[Even with New Treatment Advances for Metastatic Castration-Sensitive Prostate Cancer, There Is Still Opportunity to Bring in Radiopharmaceutical Therapy](#)

- ◇ With the PEACE-11 and ARASENS2 publications, the concept of triple combination therapy with androgen deprivation therapy (ADT), novel androgen pathway inhibitor, and docetaxel chemotherapy for front line treatment of patients with metastatic castration-sensitive prostate cancer is now ripe for digestion.
- ◇ August 2022

[Phase 3 ARASENS Trial Discussion - Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer](#)

- ◇ The 37th Annual European Association of Urology Congress held in Amsterdam, the Netherlands between July 1st, and 4th 2022 was host to prostate cancer "Game-Changing Session". Professor Jan Philipp Radtke led a discussion session following Dr. Tombal's presentation: "Overall Survival with Darolutamide versus placebo in combination with androgen deprivation therapy and docetaxel by stratification factors in the phase 3 ARASENS trial".
- ◇ July 2022

[Understanding the Mechanisms of Exercise as a Medicine to Increase Survival of Men with Prostate Cancer](#)

- ◇ The association between increased cancer specific survival, amount and intensity of physical activity is well-established across a range of cancers including for men with cancer of the prostate.
- ◇ August 2022

[Improved Prostate Cancer Diagnosis Using Hybrid Multi-Dimensional MRI](#)

- ◇ While prostate MRI is increasingly being used in the diagnosis of prostate cancer, histologic analysis after an invasive procedure (biopsies) remains the gold standard.
- ◇ March 2022

[Major Adverse Cardiovascular Event Risk Following Androgen Deprivation Therapy Initiation by Cardiovascular History](#)

- ◇ Dr. Crawford presented the results of his group's study evaluating risk of major adverse cardiovascular events (MACE) following androgen deprivation therapy (ADT) initiation by cardiovascular (CV) history.
- ◇ July 2022

[BRCA1/2 and ATM Mutated Metastatic Prostate Cancers May Present With Low Serum PSA](#)

- ◇ PARP inhibitors have previously shown survival benefits in mCRPC patients with homologous recombination repair (HRR) genes (BRCA1/2, and ATM) mutations. Germline panel test of the HRR genes and tumor tissue next generation sequencing are guideline recommended in men with metastatic prostate cancer.
- ◇ July 2022

Videos:

Theranostics in Prostate Cancer Management - The theraP Trial

- ◇ In this conversation, Matthew Cooperberg and Michael Hofman discuss areas of development in the diagnostic and theranostic spaces in prostate cancer management.
- ◇ July 2022

No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial

- ◇ Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment landscape for mHSPC has become increasingly complex during the last several years.
- ◇ July 2022

Lessons Learned in the STAMPEDE Trial

- ◇ Nicholas James joins Phillip Koo at the 13th International Uro-Oncology Conference in Brazil to discuss his presentation on the lessons learned from the STAMPEDE trial which shed insight into how we can improve the outcomes for men with metastatic prostate cancer.
- ◇ April 2022

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study

- ◇ In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study.
- ◇ August 2022

EVENT/Research Studies:



CCSN is recruiting members for a Prostate Cancer Patient, Survivor, & Caregiver Advisory Committee to create a new prostate cancer aggregator website over the next year. Monthly Zoom meetings will be held.

Contact: Jackie Manthorne at 613-898-1871 or jmanthorne@survivornet.ca

News of Interest:

Everyone:

[Clinical Case Debate: Immunotherapy Versus Alternative Therapies in the Neoadjuvant and Adjuvant Setting of Localized, High-Risk Prostate Cancer](#)

[What interventions affect the psychosocial burden experienced by prostate cancer patients undergoing active surveillance? A scoping review](#)

- ◇ Radical prostatectomy (RP) with or without extended pelvic lymph node dissection (ePLND) represents the most commonly adopted treatment modality for patients with non-metastatic prostate cancer (PCa). Although RP is associated with excellent long-term oncologic outcomes, more than 50% of patients with high-risk PCa according to preoperative features experience recurrence after surgery.
- ◇ January 2022

- ◇ Living with untreated prostate cancer (PCa) may cause anxiety and uncertainty in men undergoing active surveillance (AS). Developing a psychosocial support program for such patients might promote psychosocial well-being and patient engagement. This review aims to identify interventions with the potential to influence the psychosocial burden of prostate cancer patients undergoing AS.
- ◇ January 2022

[Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes](#)

[A Brief Overview of the Effects of Exercise and Red Beets on the Immune System in Patients with Prostate Cancer](#)

- ◇ The goal of prostate cancer focal therapy is to achieve oncologic control while reducing the rate of adverse events associated with whole-gland treatments. Numerous focal therapy modalities are currently available with early data demonstrating highly variable rates of cancer control and preservation of sexual/urinary function.
- ◇ March 2022

- ◇ Research over the past few decades has focused on the use of functional ingredients such as an active lifestyle and proper diet as a treatment for many diseases in the world. Recent studies have shown a variety of health benefits for red beets and their active ingredients such as antioxidant, anti-inflammatory, anti-cancer, blood pressure and fat reduction, anti-diabetic, and anti-obesity effects.
- ◇ May 2022

Thank you to our Sponsors and Community Partners



[PROSTADID Calgary](#) On-Line

